[1]Fengkui Zhang,et,al.Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial.2024 ASH.Abstract 304. [2]李燕娟, 等....
汇报时间:Sunday, December 8, 2024: 1:00 PM 汇报地点:Room 11 (San Diego Convention Center) 19 摘要号:663 标题:Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess ...
Prospective abstract submitters should take note of several changes for the 2024 ASH Annual Meeting. No figures or tables may be included in abstract submissions. This change is being made for greater consistency and efficiency in the review process. While only text is allowed in abstracts, figure...
编者按:2024年12月7日~12月10日美国血液学年会(ASH)在美国圣地亚哥隆重举行,作为全球血液学领域规模最大、涵盖最全面的国际学术盛会之一,每年吸引着成千上万名来自世界各地的专家学者,分享最前沿的血液学进展和突破性临床数据。「医悦汇」分享入选的6项Late Breaking Abstract(LBA)以飨读者。 背景 遗传性和获得性红...
$传奇生物(LEGN)$$金斯瑞生物科技(01548)$美国东部时间2024年11月5日上午9点,2024年ASH年度大会的abstract就会在网上公开(如果是Late Breaking Abstract的话,那么会在2024年11月25日公开)。在本年度的会议上,Arcellx和吉利德合作开发的BCMA靶点CAR-T药物Anito-cel也会发布iMMagine-1二期临床数据(NCT05396885,4L或以...
编者按:2024年12月7日~12月10日美国血液学年会(ASH)在美国圣地亚哥隆重举行,作为全球血液学领域规模最大、涵盖最全面的国际学术盛会之一,每年吸引着成千上万名来自世界各地的专家学者,分享最前沿的血液学进展和突破性临床数据。「医悦汇」分享入选的6项Late Breaking Abstract(LBA),以飨读者。
Abstract#: 1443 Session:613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I Time:Saturday, December 7, 2024; 5:30 PM - 7:30 PM First Author:Prof. Jingliao Zhang, Institute of Hematology and Blood Diseases Ho...
If none of the abstract authors is an ASH member, the abstract must be sponsored by a current ASH member. ASH members are urged to use their best judgment in restricting sponsorship to a reasonable number of abstracts, keeping in mind that they are endorsing the authenticity and quality of ...
December 7-10, 2024 会场/Venue: San Diego Convention Center, San Diego, CA, USA ASH Annual Meeting & Exposition——The premier event in malignant and non-malignant hematology 摘要征文投稿: KEY DATES-关键日期 Abstract Submission Site Opens/摘要提交开始 ...
Conference abstractAbstract only Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients Francesca Gay, Wilfried Roeloffze...